Related Experiment Video
Updated: Jul 4, 2026
08:49
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
Flutamide suppressed prostate hypertrophy in rats and mice
1Department of Pharmacology, School of Pharmacy, Shanghai Medical University, China.
Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica
|May 8, 2000
Summary
Flutamide (Flu) effectively suppresses benign prostate hypertrophy by reducing prostate weight and volume in animal models. This non-steroidal anti-androgen demonstrated a dose-dependent suppressive effect, outperforming estradiol in some aspects.
Area of Science:
- Endocrinology
- Urology
- Pharmacology
Background:
- Benign prostate hypertrophy (BPH) is a common condition in aging men.
- Hormonal imbalances, particularly androgens, play a key role in BPH development.
- Effective therapeutic strategies for BPH are continuously sought.
Purpose of the Study:
- To investigate the suppressive effects of flutamide (Flu) on benign prostate hypertrophy.
- To evaluate the efficacy of flutamide in preclinical models of BPH.
Main Methods:
- Flutamide (Flu) was administered at doses of 10, 25, and 50 mg/kg.
- The study utilized two animal models: orchiectomized rats treated with testosterone and mice with implanted fetal urogenital sinus.
- Prostate weight, volume, acini morphology, and epithelial cell height were assessed.
Main Results:
- Flutamide demonstrated a dose-dependent suppression of prostate weight and volume in rats, reducing them to 10%-50% of control levels.
- Histological analysis revealed atrophy of prostatic acini and decreased epithelial cell height following flutamide treatment.
- While flutamide reduced mouse prostate weight and volume, estradiol showed a more consistent dose-response relationship in this specific model.
Conclusions:
- Flutamide exhibits significant suppressive activity against benign prostate hypertrophy.
- The findings suggest flutamide as a potential therapeutic agent for managing BPH.
- Further research may explore flutamide's comparative efficacy and safety profile against existing BPH treatments.
